Literature DB >> 10961891

European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.

I Anagnostopoulos1, M L Hansmann, K Franssila, M Harris, N L Harris, E S Jaffe, J Han, J M van Krieken, S Poppema, T Marafioti, J Franklin, M Sextro, V Diehl, H Stein.   

Abstract

Paraffin blocks and clinical data from 521 patients with lymphocyte predominance Hodgkin disease (LPHD) diagnosed between 1970 and 1994 were collected from 16 European and United States oncological centers to establish the pathologic and clinical characteristics of a large patient cohort, to determine how frequent T-cell-rich large B-cell lymphoma (TCRLBCL) is among LPHD, and to find differential diagnostic criteria distinguishing between the 2 lymphoma categories. For this purpose, conventionally and immunohistologically stained sections were reviewed by a panel of hematopathologists. The diagnosis of LPHD was confirmed in only 219 of the 388 assessable cases (56.5%). This low confirmation rate was due mainly to the presence of a new variant of classical Hodgkin disease (CHD), which resembled, in terms of nodular growth and lymphocyte-richness, nodular LPHD and, in terms of the immunophenotype of the tumor cells, CHD and was designated nodular lymphocyte-rich CHD (NLRCHD). The nodules of LRCHD consisted-as in nodular LPHD-predominantly of B cells but differed from those present in LPHD in that they represented expanded mantle zones with atrophic germinal centers. Clinically, patients with LPHD and NLRCHD showed similar disease characteristics at presentation but differed in the frequency of multiple relapses and prognosis after relapse. Patients with LPHD and NLRCHD clearly differed from patients with CHD with nodular sclerosis or mixed cellularity, as they presented with an earlier disease stage and infrequent mediastinal involvement. As 97% of the LPHD cases showed a complete or partial nodular growth pattern, their differentiation from TCRLBCL was a rare problem in the present series. (Blood. 2000;96:1889-1899)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961891

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

Review 1.  Nodular lymphocyte-predominant Hodgkin's lymphoma.

Authors:  Lucia Nogovà; Volker Diehl; Andreas Engert
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 3.952

2.  Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.

Authors:  S Hartmann; B Schuhmacher; T Rausch; L Fuller; C Döring; M Weniger; A Lollies; C Weiser; L Thurner; B Rengstl; U Brunnberg; M Vornanen; M Pfreundschuh; V Benes; R Küppers; S Newrzela; M-L Hansmann
Journal:  Leukemia       Date:  2015-12-10       Impact factor: 11.528

Review 3.  Diagnosis of Hodgkin lymphoma in the modern era.

Authors:  Hao-Wei Wang; Jayalakshmi P Balakrishna; Stefania Pittaluga; Elaine S Jaffe
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

4.  Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group.

Authors:  Ramona Vesna Untanu; Jason Back; Burton Appel; Qinglin Pei; Lu Chen; Allen Buxton; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz; Robert E Hutchison
Journal:  Pediatr Blood Cancer       Date:  2017-08-12       Impact factor: 3.167

Review 5.  [Update on nodular lymphocyte predominant Hodgkin's lymphoma and related lesions].

Authors:  S Hartmann; M-L Hansmann
Journal:  Pathologe       Date:  2017-02       Impact factor: 1.011

Review 6.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

Review 7.  Lymphocyte predominant Hodgkin's disease.

Authors:  Bradley C Ekstrand; Sandra J Horning
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

8.  EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults.

Authors:  Alison R Huppmann; Alina Nicolae; Graham W Slack; Stefania Pittaluga; Theresa Davies-Hill; Judith A Ferry; Nancy Lee Harris; Elaine S Jaffe; Robert P Hasserjian
Journal:  Am J Surg Pathol       Date:  2014-03       Impact factor: 6.394

9.  Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group.

Authors:  Burton E Appel; Lu Chen; Allen Buxton; Suzanne L Wolden; David C Hodgson; James B Nachman
Journal:  Pediatr Blood Cancer       Date:  2012-07-27       Impact factor: 3.167

10.  Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.

Authors:  Leticia Quintanilla-Martinez; Daphne de Jong; Antoine de Mascarel; Eric D Hsi; Philip Kluin; Yaso Natkunam; Marie Parrens; Stefano Pileri; German Ott
Journal:  J Hematop       Date:  2009-12-22       Impact factor: 0.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.